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EC patients as an alternative to the labor-inten-
sive and expensive immunohistochemical pro-
cedures used to detect this chemokine receptor 
expression on cancer cells. Thus, the authors as-
sumed a relationship between the degree of lo-
cal CXCR2 expression on EC cells and its serum 
concentration. Indeed, they found significantly 
higher serum CXCR2 levels in EC patients than 
in healthy controls. However, their study failed 
to show any relationship between serum CXCR2 
concentrations and the clinical and pathologi-
cal EC characteristics, found in studies on the 
expression of CXCR2 on EC cells.7,8 The authors 
emphasized that they carried out the first study 
evaluating serum CXCR2 concentrations in EC 
patients. Therefore, they could not present any 
data on the relationship between serum CXCR2 
and its expression on EC cells. There are also no 
such data for other cells expressing CXCR2. Solu-
ble CXCR2 (sCXCR2), present and measurable in 
biological fluids (plasma, urine), is an acidic glyco-
peptide identified as the N-terminal fragment of 
the CXCR2 molecule. It is released after proteolyt-
ic cleavage of CXCR2 by cell-associated metallo-
proteinases as shown for neutrophils.9 Thus, the 
relationship between serum sCXCR2 and CXCR2 
expression may be complex.
The second aim of the study was to establish 
the diagnostic characteristics of CXCR2 levels in 
the diagnosis of EC and to assess the clinical use-
fulness of this test. The obtained results clearly 
demonstrated that significant differences in se-
rum CXCR2 levels between EC patients and tu-
mor-free controls do not justify the measure-
ment of this receptor to diagnose EC. CXCR2 is 
expressed on numerous cells, namely, on neutro-
phils, lymphocytes, as well as epithelial and endo-
thelial cells, and cannot be considered a tumor-
-specific marker. Therefore, its serum concentra-
tion distributions in EC patients and healthy con-
trols may overlap. The area under the receiver-
-operating characteristic curve (AUC) reflects 
the degree of overlapping of distributions. AUC 
for serum CXCR2 levels amounting to 0.681 
found in the study indicates significant overlap-
ping of distributions and poor overall diagnostic 
A tumor marker is a substance produced by or 
associated with a tumor, found in blood in con-
centrations higher than in malignancy-free sub-
jects.1 The long history of tumor markers is a little 
disappointing. They were introduced on a larger 
scale in the years 1960–1970 with the hope that 
they would enable the diagnosis of malignancies 
at an early stage and serve as screening tests. In 
fact tumor markers are mainly used to monitor 
the course of the cancer disease after radical treat-
ment. Rising concentrations of a tumor marker is 
an earlier indicator of cancer recurrence or distant 
metastases than clinical presentation and results 
of imaging studies are. Only a few tumor mark-
ers are used for screening (eg, alpha-fetoprotein 
in patients at risk for hepatocellular carcinoma 
or prostate-specific antigen together with other 
diagnostic tools to screen for prostate cancer) or 
for disease staging and prognosis.1 Currently, mo-
lecular genetic tumor markers including cell-free 
DNA seem to open up new perspectives.2,3 Due 
to still unsatisfactory detection rates of cancer at 
an early stage and limitations of currently avail-
able tumor markers, numerous candidate mark-
ers are evaluated in terms of specificity for tumor 
and diagnostic characteristics.
A good example of such an evaluation is a paper 
by Łukasiewicz-Zając et al4 reporting serum con-
centrations of receptor for interleukin 8 (IL-8) in 
patients with esophageal cancer (EC), published 
in the current issue of the Polish Archives of Inter-
nal Medicine (Pol Arch Med Wewn). In cancer, the 
immune response of the body is altered resulting 
in inflammation, angiogenesis, and suppression 
of cancer immunosurveillance.5 Cytokines, che-
mokines, and their receptors are involved in this 
process.5,6 CXCR2, an IL-8 receptor, is expressed 
in several human carcinomas including EC, and 
the IL-8/CXCR2 signaling pathway enhances can-
cer development by promotion of proliferation, 
invasion, and metastases of cancer cells, and an-
giogenesis within the tumor.6 
High expression of CXCR2 on EC cells has been 
reported to be associated with malignancy pro-
gression and poor prognosis.7,8 Łukasiewicz-Zając 
et al4 looked at serum CXCR2 concentrations in 
EDITORIAL
Not easy to become a tumor marker
Bogdan Solnica
Department of Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland
Correspondence to:
Bogdan Solnica, MD, PhD, 
Department of Clinical Biochemistry, 
Jagiellonian University Medical 
College, ul. Kopernika 15A, 
31-501 Kraków, Poland,  
phone: +48 12 421 40 06,  
e-mail: mbsolnic@cyf-kr.edu.pl
Received: November 13, 2016.
Accepted: November 14, 2016.
Published online:  
November 30, 2016.
Conflict of interests: none declared.
Pol Arch Med Wewn. 2016; 
126 (11): 845-846
doi:10.20452/pamw.3699
Copyright by Medycyna Praktyczna, 
Kraków 2016
POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2016; 126 (11)846
performance of this test. Similarly, other parame-
ters of diagnostic characteristics (sensitivity, spec-
ificity, predictive values of results) found in the 
study do not support the use of serum CXCR2 in 
the diagnosis of EC.
Assessment of diagnostic accuracy is consid-
ered the first step in evaluating a candidate mark-
er. Diagnostic accuracy should be linked to clini-
cal utility defined as the degree to which the ac-
tual use of the evaluated test is associated with 
changing health outcomes.10 The assessment of 
clinical utility should be based on the added val-
ue of the test and the results of validation and 
cost-effectiveness studies.11 These steps of eval-
uating candidate markers seem to be sometimes 
overlooked.
Thus, even the cautious conclusion of the au-
thors about the potential use of serum CXCR2 
levels in the diagnosis of EC seems to be too op-
timistic, but, indeed, further studies addressing 
this issue are required.
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